Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

AstraZeneca plcTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Recursion Pharmaceuticals Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: AstraZeneca plc is far larger — about 137.1× Recursion Pharmaceuticals Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AZNRXRX
Market Cap
$248.14B$1.81B
Sector
HealthHealth
52-Week High
$209.48$6.79
52-Week Low
$147.06$2.84
Enterprise Value
$275.41B$1.33B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX